Annelise Soulier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Annelise Soulier has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Christina Michael
Cancer Biophysics laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus
11 shared publications - Chrysovalantis Voutouri
Cancer Biophysics laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, Cyprus
11 shared publications - Fotios Mpekris
Cancer Genetics, Therapeutics and Ultrastructural Pathology Department, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
11 shared publications - Marcos Burger Ramos
Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, UK
11 shared publications - Myrofora Panagi
University of Cyprus 1 Cancer Biophysics Laboratory, Department of Mechanical Engineering Nicosia, Cyprus
11 shared publications - Oliver Matthew Thomas Pearce
Barts Cancer Institute, Queen Mary University of London
11 shared publications
Latest Publications
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
Immunotherapy has transformed cancer treatment but remains ineffective in many solid tumors, largely due to the immunosuppressive tumor microenvironment (TME). A dense/stiff extracellular matrix (ECM) can hinder immune cell infiltration, limiting therapeutic success. To overcome this challenge, we developed a live biotherapeutic platform using engineered programmable bacteria that offer advantages for delivering enzymes that normalize the TME. These nonpathogenic, commensal-derived strains are equipped with tumor-inducible promoters to deliver hyaluronidase locally and safely within the TME. Our study demonstrates that bacterial-mediated hyaluronan (HA) degradation reduces tumor stiffness, restores vascular function, and enhances immune checkpoint inhibitor efficacy in breast cancer murine models by improving immune cell infiltration and activation. Using machine learning and feature importance analysis, we identified biomarkers predictive of therapeutic response. Notably, we found that the potency of antitumor responses depends highly on baseline stiffness levels and ECM composition in relatively stiff breast tumors. In contrast, responses in less stiff colorectal cancer models characterized by low HA deposition primarily associated with immune cell composition, particularly CD8+ and CD4+ T cells and M2 macrophages. Our study showcases the potential of programmable bacteria to reshape the TME and identifies distinct tumor-dependent mechanisms of response across different tumor types, paving the way for more effective cancer treatments.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
Immunotherapy has transformed cancer treatment but remains ineffective in many solid tumors, largely due to the immunosuppressive tumor microenvironment (TME). A dense/stiff extracellular matrix (ECM) can hinder immune cell infiltration, limiting therapeutic success. To overcome this challenge, we developed a live biotherapeutic platform using engineered programmable bacteria that offer advantages for delivering enzymes that normalize the TME. These nonpathogenic, commensal-derived strains are equipped with tumor-inducible promoters to deliver hyaluronidase locally and safely within the TME. Our study demonstrates that bacterial-mediated hyaluronan (HA) degradation reduces tumor stiffness, restores vascular function, and enhances immune checkpoint inhibitor efficacy in breast cancer murine models by improving immune cell infiltration and activation. Using machine learning and feature importance analysis, we identified biomarkers predictive of therapeutic response. Notably, we found that the potency of antitumor responses depends highly on baseline stiffness levels and ECM composition in relatively stiff breast tumors. In contrast, responses in less stiff colorectal cancer models characterized by low HA deposition primarily associated with immune cell composition, particularly CD8+ and CD4+ T cells and M2 macrophages. Our study showcases the potential of programmable bacteria to reshape the TME and identifies distinct tumor-dependent mechanisms of response across different tumor types, paving the way for more effective cancer treatments.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
HA degradation by secreted bacterial hyaluronidase.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
HA degradation by secreted bacterial hyaluronidase.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
Tumor-specific colonization of live biotherapeutic.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
Tumor-specific colonization of live biotherapeutic.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
Bacterial-mediated stromal remodeling initiates rapid macrophage reprogramming and innate immune activation.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
Bacterial-mediated stromal remodeling initiates rapid macrophage reprogramming and innate immune activation.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
Live biotherapy has no observable effect on tumor growth and mouse body weight.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
Live biotherapy has no observable effect on tumor growth and mouse body weight.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
Live biotherapeutic bacteria combined with ICI treatment induce tumor regression of triple-negative breast cancer.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
Live biotherapeutic bacteria combined with ICI treatment induce tumor regression of triple-negative breast cancer.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
C35R7 live Biotherapeutic degrades HA within orthotopic colon tumors.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
C35R7 live Biotherapeutic degrades HA within orthotopic colon tumors.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
4T1 and E0771 breast tumor models are stiffer with a denser ECM than the CT26 colorectal cancer model.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Synthetic Inducible Bacteria Normalize the Microenvironment of Refractory Tumors, Potentiating Checkpoint Inhibitor Responses
4T1 and E0771 breast tumor models are stiffer with a denser ECM than the CT26 colorectal cancer model.